AR054252A1 - Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina - Google Patents

Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina

Info

Publication number
AR054252A1
AR054252A1 AR20060101526A ARP060101526A AR054252A1 AR 054252 A1 AR054252 A1 AR 054252A1 AR 20060101526 A AR20060101526 A AR 20060101526A AR P060101526 A ARP060101526 A AR P060101526A AR 054252 A1 AR054252 A1 AR 054252A1
Authority
AR
Argentina
Prior art keywords
oral pharmaceutical
pharmaceutical composition
composition containing
quinazolinamine ditosylate
ditosylate salts
Prior art date
Application number
AR20060101526A
Other languages
English (en)
Spanish (es)
Original Assignee
Smithkline Beecham Cork Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37115487&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR054252(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Cork Ltd filed Critical Smithkline Beecham Cork Ltd
Publication of AR054252A1 publication Critical patent/AR054252A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AR20060101526A 2005-04-19 2006-04-18 Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina AR054252A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67280505P 2005-04-19 2005-04-19

Publications (1)

Publication Number Publication Date
AR054252A1 true AR054252A1 (es) 2007-06-13

Family

ID=37115487

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20060101526A AR054252A1 (es) 2005-04-19 2006-04-18 Composicion farmaceutica oral que contiene sales de ditosilato de 4-quinazolinamina

Country Status (28)

Country Link
US (3) US8821927B2 (enExample)
EP (1) EP1871347B1 (enExample)
JP (1) JP5202302B2 (enExample)
KR (1) KR101356748B1 (enExample)
CN (1) CN101203211B (enExample)
AR (1) AR054252A1 (enExample)
AU (1) AU2006236423B2 (enExample)
BR (1) BRPI0609962B1 (enExample)
CA (1) CA2606207C (enExample)
CY (1) CY1118179T1 (enExample)
DK (1) DK1871347T3 (enExample)
EA (1) EA200702253A1 (enExample)
ES (1) ES2601503T3 (enExample)
HR (1) HRP20161429T1 (enExample)
HU (1) HUE030982T2 (enExample)
IL (1) IL186336A0 (enExample)
LT (1) LT1871347T (enExample)
MA (1) MA29404B1 (enExample)
MX (1) MX2007013089A (enExample)
NO (1) NO20075111L (enExample)
NZ (1) NZ562223A (enExample)
PE (1) PE20061430A1 (enExample)
PL (1) PL1871347T3 (enExample)
PT (1) PT1871347T (enExample)
SI (1) SI1871347T1 (enExample)
TW (1) TW200716204A (enExample)
WO (1) WO2006113649A1 (enExample)
ZA (1) ZA200708705B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물
WO2009137714A2 (en) * 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
EP2158913A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[(3-fluorophenyl)methoxy]phenyl]6-(5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
EP2158912A1 (en) 2008-08-25 2010-03-03 Ratiopharm GmbH Pharmaceutical composition comprising N-[3-chhloro-4-[3-fluorophenyl)methoxy)phenyl]6-[5[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]-4-quinazolinamine
WO2010099150A1 (en) * 2009-02-24 2010-09-02 Smithkline Beecham (Cork) Limited Pharmaceutical tablet and process
WO2011039759A1 (en) * 2009-09-29 2011-04-07 Natco Pharma Limited A new process for the preparation of lapatinib and its pharmaceutically acceptable salts
JP5858989B2 (ja) 2010-05-21 2016-02-10 ノバルティス アーゲー 組合せ
US20130072507A1 (en) 2010-05-21 2013-03-21 Glaxosmithkline Llc Combination
PE20131341A1 (es) 2010-08-03 2013-12-07 Altherx Inc Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP2958552B1 (en) * 2013-02-19 2017-06-21 Hexal AG Pharmaceutical composition comprising n-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]quinazolin-4-amine or a pharmaceutically acceptable salt, solvate or solvated salt thereof
WO2014170910A1 (en) 2013-04-04 2014-10-23 Natco Pharma Limited Process for the preparation of lapatinib
US9636340B2 (en) 2013-11-12 2017-05-02 Ayyappan K. Rajasekaran Kinase inhibitors
MX2017007054A (es) 2014-12-03 2018-05-02 Velicept Therapeutics Inc Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CN106389373B (zh) * 2015-07-29 2019-07-02 四川科伦药物研究院有限公司 一种二甲苯磺酸拉帕替尼片剂及其制备方法
CN106511289A (zh) * 2015-09-10 2017-03-22 湖北生物医药产业技术研究院有限公司 甲苯磺酸拉帕替尼片剂及其制备方法
CN108290824B (zh) 2015-10-23 2022-03-11 B3Ar治疗股份有限公司 索拉贝隆两性离子及其应用
CA3149796A1 (en) 2019-08-02 2021-02-11 Onehealthcompany, Inc. Anti-cancer agents for the treatment of canine cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506248A (en) * 1993-08-02 1996-04-09 Bristol-Myers Squibb Company Pharmaceutical compositions having good dissolution properties
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SK146199A3 (en) 1997-04-25 2000-06-12 Janssen Pharmaceutica Nv Farnesyltransferase inhibiting quinazolinones
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
CA2413134C (en) 2000-06-30 2010-05-11 Glaxo Group Limited Quinazoline ditosylate salt compounds
US7141576B2 (en) 2001-01-16 2006-11-28 Smithkline Beecham (Cork) Limited Cancer treatment method
AU2003221684A1 (en) 2002-04-08 2003-10-27 Smithkline Beecham Corporation Cancer treatment method comprising administering an erb-family inhibitor and a raf and/or ras inhibitor
AU2003235470A1 (en) 2002-06-19 2004-01-06 Smithkline Beecham Corporation Predictive markers in cancer therapy
KR101356748B1 (ko) * 2005-04-19 2014-02-06 스미스클라인 비이참 (코르크) 리미티드 약제 조성물

Also Published As

Publication number Publication date
BRPI0609962A2 (pt) 2011-10-11
EP1871347A1 (en) 2008-01-02
JP5202302B2 (ja) 2013-06-05
CN101203211A (zh) 2008-06-18
KR101356748B1 (ko) 2014-02-06
MX2007013089A (es) 2008-01-14
ES2601503T3 (es) 2017-02-15
HUE030982T2 (en) 2017-06-28
NO20075111L (no) 2007-11-16
MA29404B1 (fr) 2008-04-01
PT1871347T (pt) 2016-11-10
PL1871347T3 (pl) 2017-04-28
AU2006236423B2 (en) 2009-12-10
US20080206330A1 (en) 2008-08-28
US20160143909A1 (en) 2016-05-26
CA2606207A1 (en) 2006-10-26
WO2006113649A1 (en) 2006-10-26
HRP20161429T1 (hr) 2016-12-16
US20140335177A1 (en) 2014-11-13
IL186336A0 (en) 2008-01-20
DK1871347T3 (en) 2016-11-28
US8821927B2 (en) 2014-09-02
AU2006236423A1 (en) 2006-10-26
EP1871347A4 (en) 2012-10-31
SI1871347T1 (sl) 2016-11-30
ZA200708705B (en) 2009-12-30
BRPI0609962B1 (pt) 2022-01-18
LT1871347T (lt) 2016-11-10
JP2008536931A (ja) 2008-09-11
CA2606207C (en) 2014-11-18
EP1871347B1 (en) 2016-08-03
NZ562223A (en) 2010-01-29
CY1118179T1 (el) 2017-06-28
PE20061430A1 (es) 2007-01-25
CN101203211B (zh) 2012-08-08
TW200716204A (en) 2007-05-01
KR20080005557A (ko) 2008-01-14
EA200702253A1 (ru) 2008-04-28

Similar Documents

Publication Publication Date Title
ECSP077985A (es) Inhibidores de proteina cinasa derivados de pirrol (2,3-b) piridina
UY30477A1 (es) Derivados de [4,5']bipirimidinil-6,4´-diamina como inhibidores de cinasa de proteina
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
CO6331304A2 (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
ECSP10010599A (es) Derivados de tienopiridonas como activadores de proteina quinasa activados por amp (ampk)
NO20073182L (no) Indazol-karboksamidforbindelser
CY1113594T1 (el) Φουμαρικο αλας της (αλφα s, βητα r)-6-βρωμο-αλφα-[2-(διμεθυλαμινο)αιθυλ]-2-μεθοξυ-αλφα-1-ναφθαλινυλ-βητα-φαινυλ-3-κινολινοαιθανολης
UY30779A1 (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
EA201100691A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты
ECSP099357A (es) COMPUESTOS QUE MODULAN ACTIVIDAD C-FMS y/o C-KIT Y USOS PARA ELLO
BRPI0509369A (pt) azaindóis úteis como inibidores de jak e outras proteìna cinases
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
NO20074823L (no) Rasagilin-formuleringer med forbedret innholdsensartethet
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
MY148429A (en) Novel 1,4-benzothiepin-1,1-dioxide derivatives which are substituted with benzyl groups, method for producing drugs containing said compounds and use thereof
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
ATE526328T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
BRPI0920261A8 (pt) Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
GT200600316A (es) Sales de 4-metilo-n-(3-(4-metilo-imidazol-1-ilo)-5-trifluorometilo-fenilo)-3-(4-piridina-3-ilo-pirimidina-2-iloamino)- benzamida.
EA200800546A1 (ru) Бензимидазолтиофеновые соединения в качестве ингибиторов polo-подобных киназ (plk)
DE602007007985D1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20075111L (no) Farmasoytisk sammensetning
ATE441646T1 (de) 5-ht4-rezeptoragonistenverbindungen
ATE431824T1 (de) Chinolinon-carboxamid-verbindungen

Legal Events

Date Code Title Description
FA Abandonment or withdrawal